Enorama Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Enorama Pharma has a total shareholder equity of SEK33.7M and total debt of SEK333.0K, which brings its debt-to-equity ratio to 1%. Its total assets and total liabilities are SEK41.5M and SEK7.8M respectively.
Key information
1.0%
Debt to equity ratio
SEK 333.00k
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 9.62m |
| Equity | SEK 33.72m |
| Total liabilities | SEK 7.83m |
| Total assets | SEK 41.54m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ERMA's short term assets (SEK22.7M) exceed its short term liabilities (SEK7.8M).
Long Term Liabilities: ERMA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ERMA has more cash than its total debt.
Reducing Debt: ERMA's debt to equity ratio has increased from 0% to 1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ERMA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ERMA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.3% each year